Halogen Attached Directly Or Indirectly To The Diazole Ring By Acyclic Nonionic Bonding Patents (Class 548/310.4)
-
Patent number: 9243157Abstract: A method of printing a security code on an article includes applying droplets of an ink composition with an ink jet printer to a surface of an article to print an encrypted code. The ink composition includes an organic solvent, a binder resin, and a luminescent dye.Type: GrantFiled: January 25, 2013Date of Patent: January 26, 2016Inventors: Michael Kozee, Jeffrey Pierce, Michael Sullivan, Linfang Zhu
-
Patent number: 9000187Abstract: The invention relates to oral, topical or injectable compositions for combating liver fluke parasites in mammals, comprising at least one benzimidazole derivative active agent. The invention also provides for an improved method for eradicating and controlling liver fluke parasite infections and infestations in a mammal comprising administering the compositions of the invention to the mammal in need thereof.Type: GrantFiled: April 18, 2013Date of Patent: April 7, 2015Assignee: Merial, Inc.Inventor: Charles Q Meng
-
Publication number: 20150005505Abstract: A process for the production of a compound of formula (III) which comprises a step of reacting a compound of formula (I) with an excess amount of a compound of formula (II) in absence of aromatic solvent, wherein n is 0, 1, 2, 3 or 4; X is NH, O or S; each R1 group may be the same or different, and is independently selected from the group consisting of hydrogen, hydroxyl, alkoxy, alkyl, carbonyl, carboxyl, carboxylic acid ester, amido, cyano, halogenated aliphatic, nitro, and amino; and R2 group is selected from the group consisting of hydroxyl, Cl, F, Br, amino, and alkoxy.Type: ApplicationFiled: February 20, 2012Publication date: January 1, 2015Applicant: RHODIA OPERATIONSInventors: Tao Zhang, Claude Mercier, Olivier Buisine
-
Publication number: 20140370418Abstract: The invention relates to a monomer (6, 14) carrying an imidazole-type heterocycle (3). According to the invention, the chemical structure of said monomer (6, 14) comprises at least one unit of formula (I) wherein R1 comprises an alkenyl grouping and R2 comprises a grouping for protecting one of the nitrogen atoms of the heterocycle. The invention also relates to a monomer carrying a benzimidazole-type heterocycle, and to protected polymers obtained from said monomers, deprotected polymers produced by the protected polymers, a proton exchange membrane based on deprotected polymers, and a fuel cell provided with said membrane. Furthermore, the invention relates to methods for producing the above-mentioned monomers and polymers.Type: ApplicationFiled: September 4, 2014Publication date: December 18, 2014Applicants: PEUGEOT CITROEN AUTOMOBILES S.A., CNRS (CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE)Inventors: Xavier Glipa, Bruno Ameduri, Louis Delon, Deborah Jones, Jacques Roziere, Guillaume Frutsaert
-
Publication number: 20140127556Abstract: A lithium salt is disclosed. The lithium salt includes a lithium ion and an anion represented by formula (I), wherein R1 to R5 are independently selected from hydrogen atom, cyano group, fluorine atom, and C1-C5 alkyl group, in which the C1-C5 alkyl group is substituted with at least one fluorine atom. The present invention further provides an electrolyte solution and a lithium battery containing the lithium salt to enable a high conductivity of the battery at a high temperature.Type: ApplicationFiled: October 30, 2013Publication date: May 8, 2014Applicant: China Petrochemical Development Corporation, Taipei (Taiwan)Inventor: Fu-Ming Wang
-
Patent number: 8598078Abstract: Compounds of Formula I wherein the substituents are as defined in Claim 1, and the agrochemically acceptable salts and all stereoisomers and tautomeric forms of the compounds of formula I can be used as agrochemical active ingredients and can be prepared in a manner known per se.Type: GrantFiled: August 21, 2008Date of Patent: December 3, 2013Assignee: Syngenta Crop Protection, LLCInventors: Olivier Loiseleur, Roger Graham Hall, André Denis Stoller, Gerald Wayne Craig, André Jeanguenat, Andrew Edmunds
-
Publication number: 20130281392Abstract: The invention relates to oral, topical or injectable compositions for combating liver fluke parasites in mammals, comprising at least one benzimidazole derivative active agent. The invention also provides for an improved method for eradicating and controlling liver fluke parasite infections and infestations in a mammal comprising administering the compositions of the invention to the mammal in need thereof.Type: ApplicationFiled: April 18, 2013Publication date: October 24, 2013Applicant: MERIAL LIMITEDInventor: Charles Q. Meng
-
Patent number: 8501957Abstract: Benzimidazole compounds of formula (I): wherein R1, R2, R3, R4, R5, X, Y, Z1, and Z2 are defined herein. Also disclosed is a method for treating cancer with benzimidazole compounds.Type: GrantFiled: December 10, 2009Date of Patent: August 6, 2013Assignee: China Medical UniversityInventors: Chih-Shiang Chang, Jih-Hwa Guh, Che-Ming Teng, Shiow-Lin Pan, Wei-Ling Chang, Ju-Fang Liu, Kai-Wei Chang, Sheng-Chu Kuo
-
Patent number: 8410284Abstract: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, Metabolic Syndrome, obesity, hypercholesterolemia, and hypertension.Type: GrantFiled: October 12, 2009Date of Patent: April 2, 2013Assignees: Merck Sharp & Dohme Corp, Metabasis Therapeutics, Inc.Inventors: Qun Dang, Tony S. Gibson, Hongjian Jiang, De Michael Chung, Jianming Bao, Jinlong Jiang, Andy Kassick, Ahmet Kekec, Ping Lan, Huagang Lu, Gergely M. Makara, F. Anthony Romero, Iyassu Sebhat, David Wilson, Dariusz Wodka, Brett C. Bookser
-
Publication number: 20120004384Abstract: The present invention provides an article of manufacture formed from a substrate and a benzazoloporphyrazine bound to the substrate. The article may take a variety of different forms and may be for example an electrochromic display, a molecular capacitor, a battery, a solar cell, or a molecular memory device. Methods of making such articles, along with compounds, methods and intermediates useful for making such benzazoloporphyrazines, are also described.Type: ApplicationFiled: February 25, 2011Publication date: January 5, 2012Inventors: W. Justin Youngblood, Jonathan S. Lindsey
-
Publication number: 20110124637Abstract: Provided herein are sirtuin-modulating compounds of formula (II). The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders relating to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.Type: ApplicationFiled: July 2, 2009Publication date: May 26, 2011Inventors: Chi B Vu, Jeremy S. Disch, Pui Yee Ng, Charles A. Blum, Robert B. Perni
-
Patent number: 7932399Abstract: The present invention is directed to a novel 2-substituted benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.Type: GrantFiled: January 23, 2007Date of Patent: April 26, 2011Assignee: Janssen Pharmaceutica NVInventors: Vernon C. Alford, Jr., James C. Lanter, Raymond A. Ng, Zhihua Sui
-
Publication number: 20110046378Abstract: Disclosed here in are compounds and methods of diagnosing Alzheimer's Disease or a predisposition thereto in a mammal, the method comprising administering to the mammal a diagnostically effective amount of a radiolabeled compound, wherein the compound is selected from the group consisting of radiolabeled flavones, coumarins, carbazoles, quinolinones, chromenones, imidazoles and triazoles derivatives, allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's DiseaseType: ApplicationFiled: February 17, 2009Publication date: February 24, 2011Applicant: SIEMENS MEDICAL SOLUTIONS USA, INC.Inventors: Hartmuth C. Kolb, Joseph C. Walsh, Qianwa Liang, Brian A. Duclos, Wei Zhang, Peter J.H. Scott, Kai Chen, Zhiyong Gao, Tieming Zhao, Vani P. Mocharla, Dhanalakshmi Kasi, Gang Chen, Eric Wang, Anjana Sinha, Chunfang Xia, Henry Clifton Padgett, Farhad Karimi
-
Publication number: 20100273831Abstract: The present invention is related to novel benzimidazole compounds of formula (I) having cannabinoid receptor agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals, in particular humans.Type: ApplicationFiled: December 16, 2008Publication date: October 28, 2010Inventors: Henricus Jacobus Maria Gijsen, Bie Maria Pieter Verbist, Michel Surkyn
-
Publication number: 20100261717Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.Type: ApplicationFiled: June 28, 2010Publication date: October 14, 2010Applicant: ARRAY BIOPHARMA INC.Inventors: Eli M. Wallace, Joseph P. Lyssikatos, Allison L. Marlow, T. Brian Hurley
-
Patent number: 7795446Abstract: The present invention is directed to novel benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.Type: GrantFiled: January 25, 2008Date of Patent: September 14, 2010Assignee: Janssen Pharmaceutica NVInventors: Raymond Ng, Zhihua Sui, Jihua Guan, James C. Lanter, Vernon C. Alford, Jr.
-
Patent number: 7705031Abstract: The present invention relates to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the R1, Z, Y, RA, and W groups of formula I are as defined herein. The invention also provides pharmaceutically acceptable compositions and methods of using the compositions in the treatment of various disorders.Type: GrantFiled: November 1, 2007Date of Patent: April 27, 2010Assignee: Vertex Pharmaceuticals IncorporatedInventors: Dean M. Wilson, Andreas P. Termin, Jesus E. Gonzalez, III, Nicole Zimmermann, Yulian Zhang, Lev T. D. Fanning
-
1,5,7-trisubstituted benzimidazole derivatives and their use for modulating the GABAreceptor complex
Patent number: 7700638Abstract: This invention relates to novel 1,5,7-trisubstituted benzimidazole derivatives, pharmaceutical compositions containing these compounds, and methods of treatment therewith. The compounds of the invention are useful in the treatment of central nervous system diseases and disorders, which are responsive to modulation of the GABAA receptor complex.Type: GrantFiled: October 20, 2004Date of Patent: April 20, 2010Assignees: N. V. Organon, Neurosearch A/SInventors: Niall Morton Hamilton, Susan Elizabeth Napier, Morag Ann MacCall Easson, Andrew John Cooke, Lene Teuber, Naheed Mirza, Frank Wätjen -
Patent number: 7569688Abstract: Provided is a pharmaceutical composition containing a propane-1,3-dione derivative as the active ingredient, particularly a GnRH receptor antagonist. Also, provided is a propane-1,3-dione derivative having a GnRH antagonistic effect.Type: GrantFiled: June 20, 2005Date of Patent: August 4, 2009Assignee: Astellas Pharma Inc.Inventors: Masaaki Hirano, Eiji Kawaminami, Akira Toyoshima, Hiroyuki Moritomo, Norio Seki, Ryutaro Wakayama, Minoru Okada, Toshiyuki Kusayama
-
Patent number: 7501526Abstract: This invention relates to methods of preparing the compounds of formula (V): Each variable in this formula is defined in the specification.Type: GrantFiled: January 20, 2005Date of Patent: March 10, 2009Assignee: Taigen BiotechnologyInventors: Chien-Huang Wu, Jia-Liang Zhu, Chen-Tso Tseng, Chi-Feng Yen, Kak-Shan Shia, Yibin Xiang, Gholam Hossein Hakimelahi, Ming-Chen Chou
-
Patent number: 7414138Abstract: The present invention relates to 1,3-benzoxazole or benzodiazole UV-A sunscreens and to compositions, in particular topical compositions, containing the above UV-A sunscreens.Type: GrantFiled: April 8, 2003Date of Patent: August 19, 2008Assignee: DSM IP Assets B.V.Inventor: Ulrich Huber
-
Patent number: 7348438Abstract: The present invention is directed to novel benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.Type: GrantFiled: September 26, 2005Date of Patent: March 25, 2008Assignee: Janssen Pharmaceutica N.V.Inventors: Raymond Ng, Zhihua Sui, Jihua Guan, James C. Lanter, Vernon C. Alford, Jr.
-
Patent number: 7309716Abstract: The present invention relates to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the R1, Z, Y, RA, and W groups of formula I are as defined herein. The invention also provides pharmaceutically acceptable compositions and methods of using the compositions in the treatment of various disorders.Type: GrantFiled: October 28, 2004Date of Patent: December 18, 2007Assignee: Vertex Pharmaceuticals IncorporatedInventors: Dean M. Wilson, Andreas P. Termin, Jesus E. Gonzalez, III, Nicole Zimmermann, Yulian Zhang, Lev T. D. Fanning
-
Patent number: 7271261Abstract: 2-Aryl substituted benzimidazoles and imidazo[4,5]pyridines are disclosed as inhibitors of Cds1 and useful as adjuvants to chemotherapy or radiation therapy in the treatment of cancer.Type: GrantFiled: October 18, 2002Date of Patent: September 18, 2007Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Kristen L. Arienti, Frank U. Axe, J. Guy Breitenbucher, Liming Huang, Alice Lee, Kelly J. McClure
-
Patent number: 7244847Abstract: The present invention is directed to novel benzimidazoles according to representative structures I and II, and their derivatives that possess antibacterial activity. This invention is also directed to compositions including the benzimidazole derivatives, and methods for using the same.Type: GrantFiled: February 6, 2002Date of Patent: July 17, 2007Assignee: Isis Pharmaceuticals, Inc.Inventors: Eric E. Swayze, Yun He, Punit P. Seth, Elizabeth Anne Jefferson
-
Patent number: 7160915Abstract: The present invention relates to N-methyl-substituted benzamidazole derivatives of formula (I): as defined in the specification; pharmaceutical compositions and methods of use thereof.Type: GrantFiled: July 22, 2004Date of Patent: January 9, 2007Assignee: Warner-Lambert Company, LLCInventors: Stephen Douglas Barrett, Cathlin Marie Flamme, Michael David Kaufman, Jared Bruce John Milbank, Haile Tecle, Joseph Scott Warmus
-
Patent number: 6960591Abstract: Provided is a pharmaceutical composition containing a propane-1,3-dione derivative as the active ingredient, particularly a GnRH receptor antagonist. Also, provided is a propane-1,3-dione derivative having a GnRH antagonistic effect.Type: GrantFiled: July 4, 2001Date of Patent: November 1, 2005Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Masaaki Hirano, Eiji Kawaminami, Akira Toyoshima, Hiroyuki Moritomo, Norio Seki, Ryutaro Wakayama, Minoru Okada, Toshiyuki Kusayama
-
Patent number: 6780992Abstract: The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione derivatives of the general formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them.Type: GrantFiled: December 26, 2001Date of Patent: August 24, 2004Assignees: Dr. Reddy's Laboratories Ltd., Dr. Reddy's Laboratories Inc.Inventors: Vidya Bhushan Lohray, Braj Bhushan Lohray, Rao Bheema Paraselli, Ranga Madhavan Gurram, Rajagopalan Ramanujam, Ranjan Chakrabarti, Sarma K.S. Pakala
-
Patent number: 6703410Abstract: 3-(2,4-Dichlorobenzyl)-2-methyl-N-(pentylsulfonyl)-3H-benzimidazole-5-carboxamide, a compound having hypoglycemic activity or PDE5 inhibitory effect, has three forms of crystal forms that are distinguishable by their X-ray powder diffraction values. The most crystallographically stable crystal form is useful as a drug substance for medicines. Another crystal form can be purified efficiently by crystallization, since it forms larger crystals and can be very easily isolated by filtration. Thus this crystal form is useful for purifying 3-(2,4-Dichlorobenzyl)-2-methyl-N-(pentylsulfonyl)-3H-benzimidazole-5-carboxamide.Type: GrantFiled: September 13, 2001Date of Patent: March 9, 2004Assignees: Fujisawa Pharmaceutical Co., Ltd., Daicel Chemical Industries, Ltd.Inventors: Yoshiyuki Murai, Noritsugu Yamasaki, Takafumi Imoto, Masahiro Nishikawa, Kunihiko Dohtsu
-
Patent number: 6465484Abstract: The present invention relates to compounds which inhibit tyrosine kinase enzymes, compositions which contain tyrosine kinase inhibiting compounds and methods of using tyrosine kinase inhibitors to treat tryrosine kinase-dependent diseases/conditions such as angiogenenesis, cancer, atherosclerosis, diabetic retinopathy or autoimmune diseases, in mammals.Type: GrantFiled: February 28, 2001Date of Patent: October 15, 2002Assignee: Merck & Co., Inc.Inventors: Mark T. Bilodeau, Randall W. Hungate, April M. Cunningham, Timothy J. Koester
-
Patent number: 6444694Abstract: Disclosed herein are compounds of the formula: wherein R is phenyl or substituted phenyl; or R is furyl, pyridyl or quinolinyl; R1 and R2 are hydrogen, halogen, alkyl, alkoxy, nitro, carboxyl, alkoxy-carbonyl or aryloxycarbonyl; R3 is hydrogen, alkyl, aryl or arylalkyl; R4 and R5 are hydrogen or alkyl; or a pharmaceutically acceptable salt thereof, which are useful as inhibitors of smooth muscle cell proliferation.Type: GrantFiled: June 6, 1995Date of Patent: September 3, 2002Assignee: WyethInventors: Sie-Yearl Chai, Hassan M. Elokdah, Theodore S. Sulkowski
-
Patent number: 6387938Abstract: This invention provides novel benzimidazole derivatives represented by the formula (I); a process for producing the same; a drug containing at least one of such compounds as its active ingredient, in particular, a drug for preventing and/or treating diseases exhibiting eosinophilia, bronchial asthma and allergic diseases; and an enhancer for IFN-&ggr; production, and in particular, an antitumor agent or an antiviral agent based on the action of enhancing the IFN-&ggr; production which exhibits excellent oral bioavailability.Type: GrantFiled: July 12, 2000Date of Patent: May 14, 2002Assignee: Mochida Pharmaceutical Co., Ltd.Inventors: Kiyoshi Mizuguchi, Nobuo Ohzawa, Yasuhiro Nakai, Kazuyuki Matsuura, Shuhei Ohnishi, Yutaka Kato, Tsutomu Satoh
-
Patent number: 6369235Abstract: The present invention provides compositions and methods for the treatment of HIV infection. In particular, the present invention provides non-nucleoside inhibitors of reverse transcriptase (RT), as well as methods to treat HIV infection using these non-nucleoside inhibitors of RT. In preferred embodiments, the present invention provides a novel class of substituted benzimidazoles, effective in the inhibition of human immunodeficiency virus (HIV) RT.Type: GrantFiled: February 1, 2000Date of Patent: April 9, 2002Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Christopher J. Michejda, Marshall Morningstar, Thomas Roth
-
Patent number: 6352985Abstract: A benzimidazole compound represented by the formula (I): wherein R3 is a carboxyl group, a esterified carboxyl group, an amidated carboxyl group, an amino group, an amido group, or a sulfonyl group, or their pharmaceutically acceptable salts. Because of their blood sugar-depressing effect or PDE5 inhibitory effect, these compounds or salts thereof are useful as medicines for treating impaired glucose tolerance, diabetes, diabetic complications, syndrome of insulin resistance, hyperlipidemia, atherosclerosis, cardiovascular disorders, hyperglycemia, or hypertension; or stenocardia, hypertension, pulmonary hypertension, congestive heart failure, glomerulopathy, tubulointerstitial disorders, renal failure, atherosclerosis, angiostenosis, distal angiopathy, cerebral apoplexy, chronic reversible obstructions, allergic rhinitis, urticaria, glaucoma, diseases characterized by enteromotility disorders, impotence, diabetic complications, nephritis, cancerous cachexia, or restenosis after PTCA.Type: GrantFiled: January 28, 2000Date of Patent: March 5, 2002Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Noritsugu Yamasaki, Takafumi Imoto, Yoshiyuki Murai, Takahiro Hiramura, Teruo Oku, Kouzou Sawada
-
Patent number: 6310082Abstract: Benzimidazole-4-carboxamide compounds (I) which can act as potent inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase or PARP enzyme (EC 2.4.2.30), and which thereby can provide useful therapeutic compounds for use in conjunction with DNA-damaging cytotoxic drugs or radiotherapy to potentiate the effects of the latter. In formula (I), R and R′ may each be selected independently from hydrogen, alkyl, hydroxyalkyl (e.g. CH2CH2OH), acyl (e.g. acetyl or benzoyl) or an optionally substituted aryl (e.g. phenyl) or aralkyl (e.g. benzyl or carboxybenzyl) group. R is generally a substituted phenyl group in the most preferred compounds. The compounds may also be used in the form of pharmaceutically acceptable salts or pro-drugs.Type: GrantFiled: June 16, 2000Date of Patent: October 30, 2001Assignee: Newcastle University Ventures LimitedInventors: Roger J Griffin, Alan H Calvert, Nicola J Curtin, David R Newell, Bernard T Golding
-
Patent number: 6194396Abstract: This invention relates to a heterocyclic compound of the formula wherein a group of the formula: is a group of the formula X is O, S or N-R5, R1 is lower alkyl, etc., R5 is hydrogen, lower alkyl, etc., R2 is hydrogen, halogen, lower alkyl, etc., R3 is halogen, lower alkyl, etc., R4 is amino optionally having suitable substituent(s), and A is lower alkylene, and a salt thereof, to processes for preparation thereof, and to a pharmaceutical composition comprising the same for the prevention and/or the treatment of bradykinin or its analogues mediated diseases in human being or animals.Type: GrantFiled: October 22, 1999Date of Patent: February 27, 2001Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Teruo Oku, Hiroshi Kayakiri, Shigeki Satoh, Yoshito Abe, Yuki Sawada, Takayuki Inoue, Hirokazu Tanaka